1. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators. 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288: 321-333.

2. Hulley, S., D. Grady, T. Bush, C. Furberg, D. Herrington, B. Riggs, E. Vittinghoff. (1998). Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280(7): 605-13.

3. Harman SM, Naftolin F, Brinton EA, Judelson DR.Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence. Ann N Y Acad Sci. 2005 Jun;1052:43-56.

4. Barrett-Connor E.Hormones and heart disease in women: the timing hypothesis. Am J Epidemiol. 2007 Sep 1;166(5):506-10.

5. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM.Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006 Jun;91(6):1995-2010.

6. (2002) AACE Guidelines for evaluation and treatment of hypogonadism in adult male patients - 2002 update. Endocrine Practice 8:439-456.

7. BhasinS, Fisher CE. Male Hypogonadism. http://pier.acponline.org/physicians/diseases/d169. [Date accessed: 2003 July 18] In: PIER [online database]. Philadelphia, American College of Physicians, 2003.

8. Gooren, L. J. (1994). “A ten-year safety study of the oral androgen testosterone undecanoate.” J Androl 15(3): 212-5.

9. Matsumoto, A. M. (2002). Andropause: clinical implications of the decline in serum testosterone levels with aging in men. J Gerontol A Biol Sci Med Sci 57(2): M76-99.

10. Bhasin S, Buckwalter JG. Testosterone supplementation in older men: a rational idea whose time has not yet come. J Androl. 2001 22:718-731.

11. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR; Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001 86:724-731.

12. Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 1991;73:1016-1025.

13. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, Bremner WJ, McKinlay JB.Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab. 2002 Feb;87(2):589-98.

14. Morley JE, Kaiser FE, Perry HM, 3rd, et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle- stimulating hormone in healthy older men. Metabolism 1997; 46:410-3.

15. Simon D, Preziosi P, Barrett-Connor E, Roger M, others a. The influence of aging on plasma sex hormones in men: the Telecom Study. Am J Epidemiol 1992;135:783-791.

16. Zmuda JM, Cauley JA, Kriska A, Glynn NW, Gutai JP, Kuller LH. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former Multiple Risk Factor Intervention Trial participants. Am J Epidemiol 1997;146:609-17.

17. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, Bremner WJ, McKinlay JB. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab. 2002 87:589-598.

18. Ferrini RL, Barrett-Connor E.Sex hormones and age: a cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men. Am J Epidemiol. 1998 Apr 15;147(8):750-4.

19. Dai WS, Kuller LH, LaPorte RE, Gutai JP, Falvo-Gerard L, Caggiula A.The epidemiology of plasma testosterone levels in middle-aged men. Am J Epidemiol. 1981 Dec;114(6):804-16.

20. Pollanen P, Harkonen K, Makinen J, Irjala K, Saad F, Hubler D, Oettel M, Koskenuo M, Huhtaniemi I. Facts and fictions of andropause: lessons from the Turku male Ageing Study. 1st International Congress on Male Health in Vienna, November 2001

21. Wu FCW. Subclinical hypogonadism. Abstract S22-3. Endocrine Scoeity Meetings, Philadelphia, PA, June 18-22, 2003.

22. Bremner WJ, Prinz PN. A loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab 1983;56:1278-1281.

23. Davidson JM, Chen JJ, Crapo L, Gray GD, Greenleaf WJ, Catania JA. Hormonal changes and sexual function in aging men. J Clin Endocrinol Metab 1983;57:71-77.

24. Harman SM, Tsitouras PD. Reproductive hormones in aging men I. Measurement of sex steroids, basal luteinizing hormone and Leydig cell response to human chorionic gonadotropin. J Clin Endocrinol Metab 1980;51:35-41.

25. Harman SM, Tsitouras PD, Costa PT, Blackman MR. Reproductive hormones in aging men. II. Basal pituitary gonadotropins and gonadotropin responses to luteinizing hormone-releasing hormone. J Clin Endocrinol Metab 1982;54:547-551.

26. Murono EP, Nankin HR, Lin T, Osterman J. The aging Leydig cell: VI. Response of testosterone precursors to gonadotropin in men. Acta Endocrinologica (Copenhagen) 1982; 100:455-461.

27. Nankin HR, Calkins JH. Decreased bioavailable testosterone in aging normal and impotent men. J Clin Endocrinol Metab 1986; 63:1418-1420.

28. Nieschlag E, Lammer U, Freischem CW, Langer K, Wickings EJ. Reproductive function in young fathers and grandfathers. J Clin Endocrinol Metab 1982;51:675-681.

29. Swerdloff RS, Wang C. Androgen deficiency and aging in men [see comments]. West J Med 1993;159:579-585.

30. Tenover JS, Matsumoto AM, Plymate SR, Bremner WJ. The effects of aging in normal men on bioavailable testosterone and luteinizing hormone secretion: Response to clomiphene citrate. J Clin Endocrinol Metab 1987;65:1118-1126.

31. Vermeulen A. Clinical review 24: Androgens in the aging male. J Clin Endocrinol Metab 1991; 73:221-224.

32. Zumoff B, Strain GW, Kream J, et al. Age variation of the 24 hour mean plasma concentration of androgens, estrogens, and gonadotropins in normal adult men. J Clin Endocrinol Metab 1982; 54:534-538.

33. Pirke KM, Doerr P. Age related changes and interrelationships between plasma testosterone, oestradiol and testosterone-binding globulin in normal adult males. Acta Endocrinol (Copenh) 1973; 74:792-800.

34. McKinlay JB, Longcope C, Gray A.The questionable physiologic and epidemiologic basis for a male climacteric syndrome: preliminary results from the Massachusetts Male Aging Study. Maturitas. 1989 Jun;11(2):103-15.

35. Mohr BA, Bhasin S, Link CL, O'Donnell AB, McKinlay JB.The effect of changes in adiposity on testosterone levels in older men: longitudinal results from the Massachusetts Male Aging Study. Eur J Endocrinol. 2006 Sep;155(3):443-52.

36. Orwoll E, Lambert LC, Marshall LM, Phipps K, Blank J, Barrett-Connor E, Cauley J, Ensrud K, Cummings S.Testosterone and estradiol among older men. J Clin Endocrinol Metab. 2006;91:1336-44.

37. Coviello AD, Lakshman K, Mazer NA, Bhasin S.Differences in the apparent metabolic clearance rate of testosterone in young and older men with gonadotropin suppression receiving graded doses of testosterone. J Clin Endocrinol Metab 2006;91:4669-75.

38. Ishimaru T, Pages L, Horton R. Altered metabolism of androgens in elderly men with benign prostatic hyperplasia. J Clin Endocrinol Metab. 1977 Oct;45(4):695-701.

39. Mulligan T, Iranmanesh A, Johnson ML, Straume M, Veldhuis JD. Aging alters feed-forward and feedback linkages between LH and testosterone in healthy men. Am J Physiol 1997 Oct;273(4 Pt 2):R1407-13.

40. Veldhuis JD, Zwart A, Mulligan T, Iranmanesh A. Muting of androgen negative feedback unveils impoverished gonadotropin-releasing hormone/luteinizing hormone secretory reactivity in healthy older men. J Clin Endocrinol Metab. 2001 86:529-535.

41. Winters SJ, Sherins RJ, Troen P. The gonadotropin-suppressive activity of androgen is increased in elderly men. Metabolism. 1984 33:1052-1059.

42. Winters SJ, Atkinson L. Serum LH concentrations in hypogonadal men during transdermal testosterone replacement through scrotal skin: further evidence that ageing enhances testosterone negative feedback. The Testoderm Study Group. Clin Endocrinol (Oxf) 1997; 47(3):317-322.

43. Urban RJ, Veldhuis JD, Blizzard RM, Dufau ML.Attenuated release of biologically active luteinizing hormone in healthy aging men. J Clin Invest. 1988 Apr;81(4):1020-9.

44. Zwart AD, Urban RJ, Odell WD, Veldhuis JD. Contrasts in the gonadotropin-releasing hormone dose-response relationships for luteinizing hormone, follicle-stimulating hormone and alpha-subunit release in young versus older men: appraisal with high-specificity immunoradiometric assay and deconvolution analysis. Eur J Endocrinol. 1996 135:399-406.

45. Gruenewald DA, Naai MA, Marck BT, Matsumoto AM. Age-related decrease in hypothalamic gonadotropin-releasing hormone (GnRH) gene expression, but not pituitary responsiveness to GnRH, in the male Brown Norway rat. J Androl. 2000 21:72-84.

46. Bonavera JJ, Swerdloff RS, Sinha Hakim AP, Lue YH, Wang C. Aging results in attenuated gonadotropin releasing hormone-luteinizing hormone axis responsiveness to glutamate receptor agonist N-methyl-D-aspartate. J Neuroendocrinol. 1998 10:93-99.

47. Deslypere JP, Kaufman JM, Vermeulen T, Vogelaers D, Vandalem JL, Vermeulen A. Influence of age on pulsatile luteinizing hormone release and responsiveness of the gonadotrophs to sex hormone feedback in men. J Clin Endocrinol Metab. 1987 64:68-73.

48. Mahmoud AM, Goemaere S, De Bacquer D, Comhaire FH, Kaufman JM. Serum inhibin B levels in community-dwelling elderly men. Clin Endocrinol (Oxf). 2000 53:141-147.

49. Pincus SM, Mulligan T, Iranmanesh A, Gheorghiu S, Godschalk M, Veldhuis JD.Older males secrete luteinizing hormone and testosterone more irregularly, and jointly more asynchronously, than younger males. Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14100-5.

50. Keenan DM, Veldhuis JD. Disruption of the hypothalamic luteinizing hormone pulsing mechanism in aging men. Am J Physiol Regul Integr Comp Physiol. 2001 Dec;281(6):R1917-24.

51. Morales A, Lunenfeld B; International Society for the Study of the Aging Male. Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM. International Society for the Study of the Aging Male. Aging Male. 2002 Jun;5(2):74-86

52. Andropause, Consensus Panel. (2002). Proceedings of the Andropause Consensus Panel, The Endocrine Society.

53. Bhasin S, Tenover JS. Age-associated sarcopenia--issues in the use of testosterone as an anabolic agent in older men. J Clin Endocrinol Metab 1997(b);82:1659-1660.

54. Perry HM 3rd, Miller DK, Patrick P, Morley JE.Testosterone and leptin in older African-American men: relationship to age, strength, function, and season. Metabolism 2000;49:1085-91.

55. Melton LJ, 3rd, Khosla S, Riggs BL. Epidemiology of sarcopenia. Mayo Clin Proc 2000; 75 Suppl:S10-2; discussion S12-3.

56. Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among the elderly in New Mexico [published erratum appears in Am J Epidemiol 1999 Jun 15;149(12):1161]. Am J Epidemiol 1998; 147:755-63.

57. Baumgartner RN, Waters DL, Gallagher D, Morley JE, Garry PJ.Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev. 1999;107:123-36.

58. Holloszy JO. Workshop on sarcopenia: muscle atrophy in old age. J Gerontol 1995; 50A Spec No:1-161.

59. Dutta C, Hadley EC. The significance of sarcopenia in old age. J Gerontol A Biol Sci Med Sci 1995; 50 Spec No:1-4.

60. Kohrt WM, Malley MT, Dalsky GP, Holloszy JO. Body composition of healthy sedentary and trained, young and older men and women. Med Sci Sports Exerc 1992; 24:832-7.

61. American Medical Association white paper on elderly health. Report of the Council on Scientific Affairs [published erratum appears in Arch Intern Med 1991;151(2):265]. Arch Intern Med 1990; 150:2459-72.

62. Borkan GA, Hults DE, Gerzof SG, Robbins AH, Silbert CK. Age changes in body composition revealed by computed tomography. J Gerontol 1983;38:673-7.

63. Borkan GA, Norris AH. Fat redistribution and the changing body dimensions of the adult male. Hum Biol 1977; 49:495-513.

64. Cohn, SH, Vartsky D, Yasumura S, Sawitsky A, Zanzi I, Vaswani A, Ellis KJ. Compartmental body composition based on total-body nitrogen, potassium, and calcium. Am J Physiol 1980;239:E524-E530.

65. Novak, LP. 1972 Aging, total body potassium, fat free-mass, and cell mass in males and females between ages 18-85 years. J Gerontol 1972;27:438-443.

66. Schoeller, DA. Changes in total body water with age. Am J Clin Nutr 1989;50:1176-1181

67. Evans, WJ. 1995 Effects of exercise on body composition and functional capacity of the elderly. J Gerontol 50A:147-150

68. Flegg, JL and Lakatta, ED. Role of muscle loss in the age-associated reductions in VO2max. J Appl Physiol 1988;65:1147-1151

69. Proctor, DN, Balagopal, P and Nair, KS. Age-related sarcopenia in humans is associated with reduced synthetic rates of specific muscle proteins. J Nutr 1998;128:351S-355S.

70. Lexell, J, Henriksson-Larsen, K, Wimblod, B and Sjostrom, M. Distribution of different fiber types in human skeletal muscles: effects of aging studied in whole muscle cross section. Muscle Nerve 1983;6:588-595

71. Lexell, J. Human aging, muscle mass, and fiber type composition. J Gerontol. 1995;50A:11-16

72. Frontera, WR, Hughes, VR, Lutz, KJ and Evans, WJ. A cross-sectional study of muscle strength and mass in 45- to 75- yr-old men and women. J Appl Physiol 1991;71:644-650.

73. Harris, T. Muscle mass and strength: relation to function in population studies. J Nutr. 1997;27:1004S-1006S

74. Skelton, DA, Greig, CA, Davies, JM and Young, A. Strength, power, and related functional ability of healthy people aged 65-89 years. Age Aging 1995;23:371-377.

75. Roy TA, Blackman MR, Harman SM, Tobin JD, Schrager M, Metter EJ.Interrelationships of serum testosterone and free testosterone index with FFM and strength in aging men. Am J Physiol Endocrinol Metab. 2002 Aug;283(2):E284-94.

76. O'Donnell AB, Travison TG, Harris SS, Tenover JL, McKinlay JB.Testosterone, dehydroepiandrosterone, and physical performance in older men: results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2006 Feb;91(2):425-31.

77. Mohr BA, Bhasin S, Kupelian V, Araujo AB, O'Donnell AB, McKinlay JB.Testosterone, sex hormone-binding globulin, and frailty in older men. J Am Geriatr Soc. 2007 Apr;55(4):548-55.

78. van den Beld AW, de Jong FH, Grobbee DE, Pols HA, Lamberts SW.Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab. 2000 Sep;85(9):3276-82.

79. Schaap LA, Pluijm SM, Smit JH, van Schoor NM, Visser M, Gooren LJ, Lips P.The association of sex hormone levels with poor mobility, low muscle strength and incidence of falls among older men and women. Clin Endocrinol (Oxf). 2005 Aug;63(2):152-60.

80. Orwoll E, Lambert LC, Marshall LM, Blank J, Barrett-Connor E, Cauley J, Ensrud K, Cummings SR; Osteoporotic Fractures in Men Study Group.Endogenous testosterone levels, physical performance, and fall risk in older men. Arch Intern Med. 2006 Oct 23;166(19):2124-31.

81. Travison TG, Morley JE, Araujo AB, O'Donnell AB, McKinlay JB.The relationship between libido and testosterone levels in aging men. J Clin Endocrinol Metab. 2006 Jul;91(7):2509-13.

82. Zitzmann M, Faber S, Nieschlag E.Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab. 2006 Nov;91(11):4335-43.

83. Marberger M, Roehrborn CG, Marks LS, Wilson T, Rittmaster RS.Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia. J Clin Endocrinol Metab. 2006 Apr;91(4):1323-8.

84. Araujo AB, Esche GR, Kupelian V, O'donnell AB, Travison TG, Williams RE, Clark RV, McKinlay JB.Prevalence of Symptomatic Androgen Deficiency in Men. J Clin Endocrinol Metab. 2007 Aug 14; [Epub ahead of print]

85. Kaiser FE, Viosca SP, Morley JE, Mooradian AD, Davis SS, Korenman SG. Impotence and aging: clinical and hormonal factors. J Am Geriatr Soc 1988;36:511-9.

86. Korenman SG, Morley JE, Mooradian AD, et al. Secondary hypogonadism in older men: its relation to impotence. J Clin Endocrinol Metab 1990; 71:963-9.

87. Dodge HH, Du Y, Saxton JA, Ganguli M.Cognitive domains and trajectories of functional independence in nondemented elderly persons. J Gerontol A Biol Sci Med Sci. 2006 Dec;61(12):1330-7.

88. Kawas CH, Corrada MM, Brookmeyer R, Morrison A, Resnick SM, Zonderman AB, Arenberg D.Visual memory predicts Alzheimer's disease more than a decade before diagnosis. Neurology. 2003 Apr 8;60(7):1089-93.

89. Liu-Ambrose T, Pang MY, Eng JJ.Executive function is independently associated with performances of balance and mobility in community-dwelling older adults after mild stroke: implications for falls prevention. Cerebrovasc Dis. 2007;23(2-3):203-10.

90. van Schoor NM, Smit JH, Pluijm SM, Jonker C, Lips P.Different cognitive functions in relation to falls among older persons. Immediate memory as an independent risk factor for falls. J Clin Epidemiol. 2002 Sep;55(9):855-62.

91. Hier DB, Crowley WF Jr.Spatial ability in androgen-deficient men. N Engl J Med. 1982 May 20;306(20):1202-5.

92. Janowsky JS, Oviatt SK, Orwoll ES.Testosterone influences spatial cognition in older men. Behav Neurosci. 1994 Apr;108(2):325-32.

93. Janowsky JS, Chavez B, Orwoll E.Sex steroids modify working memory. J Cogn Neurosci. 2000 May;12(3):407-14.

94. Janowsky JS.The role of androgens in cognition and brain aging in men. Neuroscience. 2006;138(3):1015-20.

95. Fales CL, Knowlton BJ, Holyoak KJ, Geschwind DH, Swerdloff RS, Gonzalo IG.Working memory and relational reasoning in Klinefelter syndrome. J Int Neuropsychol Soc. 2003 Sep;9(6):839-46.

96. Temple CM, Sanfilippo PM.Executive skills in Klinefelter's syndrome. Neuropsychologia. 2003;41(11):1547-59.

97. Alexander GM, Swerdloff RS, Wang C, Davidson T, McDonald V, Steiner B, Hines M.Androgen-behavior correlations in hypogonadal men and eugonadal men. II. Cognitive abilities. Horm Behav. 1998 Apr;33(2):85-94.

98. Christiansen K. Sex hormone-related variations of cognitive performance in !Kung San hunter-gatherers of Namibia. Neuropsychobiology 1993; 27:97-107.

99. Barrett-Connor E, Goodman-Gruen D, Patay B. Endogenous sex hormones and cognitive function in older men. J Clin Endocrinol Metab 1999(a);84:3681-5.

100. Gouchie C, Kimura D. The relationship between testosterone levels and cognitive ability patterns. Psychoneuroendocrinology 1991; 16:323-34.

101. Shute VJ PJ, Hubert L, Reynolds RW. The relationship between androgen levels and human spatial abilities. Bull Psychonomic Soc 1983; 21:465-468.

102. Margolese HC. The male menopause and mood: testosterone decline and depression in the aging male--is there a link? J Geriatr Psychiatry Neurol 2000;13(2):93-101

103. Barrett-Conner E, Von Muhlen DG, Kritz-Silverstein D. Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo study. J Clin Endocrinol Metab 1999(b);84:573-577.

104. Van Honk J, Tuiten A, Verbaten R, van den Hout M, Koppeschaar H, Thijssen J, de Haan E. Correlations among salivary testosterone, mood, and selective attention to threat in humans. Hormones Behav 1999; 36:17-24.

105. Seidman SN, Araujo AB, Roose SP, McKinlay JB.Testosterone level, androgen receptor polymorphism, and depressive symptoms in middle-aged men. Biol Psychiatry. 2001 Sep 1;50(5):371-6.

106. Seidman SN, Araujo AB, Roose SP, Devanand DP, Xie S, Cooper TB, McKinlay JB.Low testosterone levels in elderly men with dysthymic disorder. Am J Psychiatry. 2002 Mar;159(3):456-9.

107. Delhez M, Hansenne M, Legros JJ.Andropause and psychopathology: minor symptoms rather than pathological ones. Psychoneuroendocrinology. 2003 Oct;28(7):863-74.

108. Fink HA, Ewing SK, Ensrud KE, Barrett-Connor E, Taylor BC, Cauley JA, Orwoll ES.Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men.J Clin Endocrinol Metab. 2006 Oct;91(10):3908-15.

109. Greendale GA, Edelstein S, Barrett-Connor E. Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study. J Bone Miner Res 1997;12:1833-43.

110. Amin S, Zhang Y, Sawin CT, Evans SR, Hannan MT, Kiel DP, Wilson PW, Felson DT.Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham study. Ann Intern Med. 2000 Dec 19;133(12):951-63.

111. Khosla S, Melton LJ III, Atkinson EJ, et al. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 1998;83:2266-2274.

112. Center JR, Nguyen TV, Sambrook PN, Eisman JA. Hormonal and biochemical parameters in the determination of osteoporosis in elderly men. J Clin Endocrinol Metab 1999;84:3626-3635.

113. Boonen S, Vanderscheren D, Geusens P, Bouillon R. Age-associated endocrine deficiencies as potential determinants of femoral neck (type II) osteoporotic fracture occurrence in elderly men. Int J Androl 1997;20:134-143.

114. Khosla S, Melton LJ 3rd, Robb RA, Camp JJ, Atkinson EJ, Oberg AL, Rouleau PA, Riggs BL.Relationship of volumetric BMD and structural parameters at different skeletal sites to sex steroid levels in men. J Bone Miner Res. 2005 May;20(5):730-40.

115. Mellstrom D, Johnell O, Ljunggren O, Eriksson AL, Lorentzon M, Mallmin H, Holmberg A, Redlund-Johnell I, Orwoll E, Ohlsson C.Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden. J Bone Miner Res. 2006 Apr;21(4):529-35.

116. Shores MM, Moceri VM, Gruenewald DA, Brodkin KI, Matsumoto AM, Kivlahan DR.Low testosterone is associated with decreased function and increased mortality risk: a preliminary study of men in a geriatric rehabilitation unit. J Am Geriatr Soc. 2004 Dec;52(12):2077-81.

117. Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR.Low serum testosterone and mortality in male veterans. Arch Intern Med. 2006 Aug 14-28;166(15):1660-5.

118. Araujo AB, Kupelian V, Page ST, Handelsman DJ, Bremner WJ, McKinlay JB.Sex steroids and all-cause and cause-specific mortality in men. Arch Intern Med. 2007 Jun 25;167(12):1252-60.

119. Laughlin GA, Barrett-Connor E, Bergstrom J.Low Serum Testosterone and Mortality in Older Men. J Clin Endocrinol Metab. 2007 Oct 2; [Epub ahead of print]

120. Litman HJ, Bhasin S, O'Leary MP, Link CL, McKinlay JB; BACH Survey Investigators.An investigation of the relationship between sex-steroid levels and urological symptoms: results from the Boston Area Community Health survey. BJU Int. 2007 Aug;100(2):321-6. Epub 2007 May 17.

121. Alexandersen P, Haarbo J, Christiansen C. The relationship of natural androgens to coronary heart disease in males: a review. Atherosclerosis 1996; 125:1-13.

122. Barrett-Connor E, Khaw KT. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation 1988;78:539-45.

123. Cauley JA, Gutai JP, Kuller LH, Dai WS.Usefulness of sex steroid hormone levels in predicting coronary artery disease in men. Am J Cardiol. 1987 Oct 1;60(10):771-7.

124. Contoreggi CS, Blackman MR, Andres R, Muller DC, Lakatta EG, Fleg JL, Harman SM.Plasma levels of estradiol, testosterone, and DHEAS do not predict risk of coronary artery disease in men. J Androl. 1990 Sep-Oct;11(5):460-70.

125. Yarnell JW, Beswick AD, Sweetnam PM, Riad-Fahmy D.Endogenous sex hormones and ischemic heart disease in men. The Caerphilly prospective study. Arterioscler Thromb. 1993 Apr;13(4):517-20.

126. Hak AE, Witteman JC, de Jong FH, Geerlings MI, Hofman A, Pols HA.Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab. 2002 Aug;87(8):3632-9.

127. Bassey, E.J, Fiatarone, MA, O’Neill, EF, Kelly, M, Evans, WJ. 1992 Leg extensor power and functional performance in very old men and women. Clin Sci 82:321-327

128. Rantanen, T and Avela, J. Leg extension power and walking speed in very old people living independently. J Gerontol 1997;52A:M225-M23

129. Whipple, RH, Wolfson, LI and Amerman, M. 1987 The relationship of knee and ankle weakness to falls in nursing home residents: an isokinetic study. J Am Geriatr Soc 1987;35: 13-20.

130. Wolfson, L, Judge, J, Whipple, R and King, M. Strength is a major factor in balance, gait, and the occurrence of falls. J Gerontol 1995;50A:64-67

131. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM.Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006 Jun;91(6):1995-2010. Epub 2006 May 23. Erratum in: J Clin Endocrinol Metab. 2006 Jul;91(7):2688.

132. Bhasin S, Calof OM, Storer TW, Lee ML, Mazer NA, Jasuja R, Montori VM, Gao W, Dalton JT.Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab. 2006 Mar;2(3):146-59.

133. Katznelson L, Finkelstein JS, Schonenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996;81:4358-4365.

134. Bhasin S, Storer TW, Berman N, Yarasheski KE, Clevenger B, Phillips J et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997(a);82:407-413.

135. Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men--a clinical research center study. J Clin Endocrinol Metab 1992;75:1092-1098.

136. Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, Santanna J, Loh L, Lenrow DA, Holmes JH, Kapoor SC, Atkinson LE, Strom BL. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000;85(8):2670-7.

137. Wang C, Swedloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. J Clin Endocrinol Metab 2000;85(8):2839-53.

138. Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R; North American AA2500 T Gel Study Group.AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab. 2003 Jun;88(6):2673-81.

139. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, Chen X, Yarasheski KE, Magliano L, Dzekov C, Dzekov J, Bross R, Phillips J, Sinha-Hikim I, Shen R, Storer TW.Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001 281:E1172-81.

140. Storer TW, Magliano L, Woodhouse L, Lee ML, Dzekov C, Dzekov J, Casaburi R, Bhasin S.Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. J Clin Endocrinol Metab. 2003 Apr;88(4):1478-85.

141. Woodhouse LJ, Reisz-Porszasz S, Javanbakht M, Storer TW, Lee M, Zerounian H, Bhasin S.Development of models to predict anabolic response to testosterone administration in healthy young men. Am J Physiol Endocrinol Metab. 2003 May;284(5):E1009-17.

142. Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men [see comments]. N Engl J Med 1996; 335:1-7.

143. Urban RJ, Bodenburg YH, Gilkison C, Foxworth J, Coggan AR, Wolfe RR et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 1995;269(5 Pt 1):E820-E826.

144. Ferrando AA, Sheffield-Moore M, Yeckel CW, Gilkison C, Jiang J, Achacosa A, Lieberman SA, Tipton K, Wolfe RR, Urban RJ.2002 Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab. 282:E601-E607.

145. Kong A, Edmonds P.Testosterone therapy in HIV wasting syndrome: systematic review and meta-analysis. Lancet Infect Dis. 2002 Nov;2(11):692-9.

146. Johns K, Beddall MJ, Corrin RC.Anabolic steroids for the treatment of weight loss in HIV-infected individuals. Cochrane Database Syst Rev. 2005 Oct 19;(4):CD005483.

147. Bhasin S, Storer TW, Javanbakht M, et al. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels [see comments]. JAMA 2000; 283:763-70.

148. Grinspoon S, Corcoran C, Askari H, Schoenfeld D, Wolf L, Burrows B, Walsh M, Hayden D, Parlman K, Anderson E, Basgoz N, Klibanski A.Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998 Jul 1;129(1):18-26.

149. Storer TW, Woodhouse LJ, Sattler F, Singh AB, Schroeder ET, Beck K, Padero M, Mac P, Yarasheski KE, Geurts P, Willemsen A, Harms MK, Bhasin S.A randomized, placebo-controlled trial of nandrolone decanoate in human immunodeficiency virus-infected men with mild to moderate weight loss with recombinant human growth hormone as active reference treatment. J Clin Endocrinol Metab. 2005 Aug;90(8):4474-82.

150. Coodley GO, Coodley MK.A trial of testosterone therapy for HIV-associated weight loss.AIDS. 1997 Sep;11(11):1347-52.

151. Grinspoon S, Corcoran C, Parlman K, Costello M, Rosenthal D, Anderson E, Stanley T, Schoenfeld D, Burrows B, Hayden D, Basgoz N, Klibanski A.Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. A randomized, controlled trial. Ann Intern Med. 2000 Sep 5;133(5):348-55.

152. Bhasin S, Storer TW, Asbel-Sethi N, Kilbourne A, Hays R, Sinha-Hikim I, Shen R, Arver S, Beall G.Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels. J Clin Endocrinol Metab. 1998 Sep;83(9):3155-62.

153. Grinspoon S, Corcoran C, Stanley T, Baaj A, Basgoz N, Klibanski A.Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men. J Clin Endocrinol Metab. 2000 Jan;85(1):60-5.

154. Morley JE, Perry HM, III, Kaiser FE, Kraenzle D, Jensen J, Houston K et al. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 1993; 41(2):149-152.

155. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992 75:1092-1098.

156. Sih R, Morley JE, Kaiser FE, Perry HM, III, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial [see comments]. J Clin Endocrinol Metab 1997;82(6):1661-1667.

157. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999; 84(8):2647-2653.

158. Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL.Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab. 2005 Mar;90(3):1502-10.

159. Schroeder ET, Singh AB, Bhasin S, Storer TW, Azen C, Davidson T, Martinez C, Sinha-Hikim I, Jaque V, Terk M, Sattler FR. The effects of an oral androgen on muscle and metabolism in older, community, dwelling men. Am J Physiol Endocrinol Metab. 2003;284(1):E120-8.

160. Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG.Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci. 2001 May;56(5):M266-72.

161. Sinha-Hikim I, Artaza J, Woodhouse L, Gonzalez-Cadavid N, Singh AB, Lee MI, Storer TW, Casaburi R, Shen R, Bhasin S.Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am J Physiol Endocrinol Metab. 2002 2831:E154-E164.

162. Sinha-Hikim I, Roth SM, Lee MI, Bhasin S.Testosterone-induced muscle hypertrophy is associated with an increase in satellite cell number in healthy, young men. Am J Physiol Endocrinol Metab. 2003 Jul;285(1):E197-205.

163. Bhasin S, Taylor WE, Singh R, Artaza J, Choi H, Sinha-Hikim I, Jasuja R, Gonzalez-Cadavid N. Mechanisms of anabolic effects of testosterone on the muscle: mesenchymal, pluripotent stem cell as the target of androgen action. J Gerontol Med Sci 2003 (in press).

164. Singh R, Artaza J, Taylor WE, Gonzalez-Cadavid N, Bhasin S. Androgens stimulate myogenesis and inhibit adipogenic differentiation in pluripotent C3H10T1/2 cells. Endocrinology 2003 (in press).

165. Singh R, Artaza JN, Taylor WE, Braga M, Yuan X, Gonzalez-Cadavid NF, Bhasin S.Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. Endocrinology. 2006 Jan;147(1):141-54.

166. Montano M, Flanagan JN, Jiang L, Sebastiani P, Rarick M, LeBrasseur NK, Morris CA, Jasuja R, Bhasin S.Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802.

167. Bartsch W, Krieg M, Voigt KD. Quantification of endogenous testosterone, 5 alpha-dihydrotestosterone and 5 alpha-androstane-3 alpha, 17 beta-diol in subcellular fractions of the prostate, bulbocavernosus/levator ani muscle, skeletal muscle and heart muscle of the rat. J Steroid Biochem. 1980 13:259-264.

168. Wilson JD.The role of 5alpha-reduction in steroid hormone physiology.Reprod Fertil Dev. 2001;13(7-8):673-8.

169. Andriole GL, Kirby R. Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 2003;44:82-8.

170. Jones ME, Thorburn AW, Britt KL, Hewitt KN, Wreford NG, Proietto J, Oz OK, Leury BJ, Robertson KM, Yao S, Simpson ER. Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity. Proc Natl Acad Sci U S A 2000;97(23):12735-40.

171. Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, Korach KS, Simpson ER.Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med. 1997 Jul 10;337(2):91-5.

172. Bhasin S, Enzlin P, Coviello A, Basson R.Sexual dysfunction in men and women with endocrine disorders. Lancet. 2007 Feb 17;369(9561):597-611.

173. Alexander G. Androgens and behavior in men. In: Wang, C., ed. Male Reproductive Function. Vol. 5. Boston: Kluwer Academic Publishers, 1999:191-205.

174. Arver S, Dobs AS, Meikle AW, Allen RP, Sanders SW, Mazer NA. Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system. J Urol 1996; 155:1604-8.

175. Bancroft J, Wu FC. Changes in erectile responsiveness during androgen replacement therapy. Arch Sex Behav 1983;12:59-66.

176. Davidson JM, Camargo CA, Smith ER. Effects of androgen on sexual behavior in hypogonadal men. J Clin Endocrinol Metab 1979; 48:955-8.

177. Kwan M, Greenleaf WJ, Mann J, Crapo L, Davidson JM. The nature of androgen action on male sexuality: a combined laboratory- self-report study on hypogonadal men. J Clin Endocrinol Metab 1983; 57:557-62.

178. Bagatell CJ, Heiman JR, Rivier JE, Bremner WJ. Effects of endogenous testosterone and estradiol on sexual behavior in normal young men [published erratum appears in J Clin Endocrinol Metab 1994 Jun;78(6):1520]. J Clin Endocrinol Metab 1994; 78:711-6.

179. Carani C, Granata AR, Bancroft J, Marrama P. The effects of testosterone replacement on nocturnal penile tumescence and rigidity and erectile response to visual erotic stimuli in hypogonadal men. Psychoneuroendocrinology 1995;20:743-53.

180. Cunningham GR, Hirshkowitz M, Korenman SG, Karacan I.Testosterone replacement therapy and sleep-related erections in hypogonadal men. J Clin Endocrinol Metab. 1990 Mar;70(3):792-7.

181. Carani C, Bancroft J, Granata A, Del Rio G, Marrama P.Testosterone and erectile function, nocturnal penile tumescence and rigidity, and erectile response to visual erotic stimuli in hypogonadal and eugonadal men. Psychoneuroendocrinology. 1992 Nov;17(6):647-54.

182. Lugg J, Ng C, Rajfer J, Gonzalez-Cadavid N. Cavernosal nerve stimulation in the rat reverses castration-induced decrease in penile NOS activity. Am J Physiol 1996; 271:E354-61.

183. Shabsigh R.The effects of testosterone on the cavernous tissue and erectile function. World J Urol. 1997;15(1):21-6. Review.

184. Mills TM, Lewis RW, Stopper VS.Androgenic maintenance of inflow and veno-occlusion during erection in the rat. Biol Reprod. 1998 Dec;59(6):1413-8.

185. Mills TM, Dai Y, Stopper VS, Lewis RW.Androgenic maintenance of the erectile response in the rat. Steroids. 1999 Sep;64(9):605-9.

186. Bhasin S, Fielder T, Peacock N, Sod-Moriah UA, Swerdloff RS. Dissociating antifertility effects of GnRH-antagonist from its adverse effects on mating behavior in male rats. Am J Physiol 1988; 254:E84-91.

187. Fielder TJ, Peacock NR, McGivern RF, Swerdloff RS, Bhasin S. Testosterone dose-dependency of sexual and nonsexual behaviors in the gonadotropin-releasing hormone antagonist-treated male rat. J Androl 1989; 10:167-73.

188. Buena F, Swerdloff RS, Steiner BS, et al. Sexual function does not change when serum testosterone levels are pharmacologically varied within the normal male range. Fertil Steril 1993; 59:1118-23.

189. Kaiser FE, Viosca SP, Morley JE, Mooradian AD, Davis SS, Korenman SG. Impotence and aging: clinical and hormonal factors. J Am Geriatr Soc 1988;36:511-9.

190. Korenman SG, Morley JE, Mooradian AD, et al. Secondary hypogonadism in older men: its relation to impotence. J Clin Endocrinol Metab 1990; 71:963-9.

191. Morley JE, Korenman SG, Mooradian AD, Kaiser FE. Sexual dysfunction in the elderly male [clinical conference]. J Am Geriatr Soc 1987; 35:1014-22.

192. Buvat J, Lemaire A. Endocrine screening in 1,022 men with erectile dysfunction: clinical significance and cost-effective strategy [see comments]. J Urol 1997; 158:1764-7.

193. Citron JT, Ettinger B, Rubinoff H, et al. Prevalence of hypothalamic-pituitary imaging abnormalities in impotent men with secondary hypogonadism. J Urol 1996;155:529-33.

194. Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab 1997;82:3793-6.

195. Jain P, Rademaker AW, McVary KT. Testosterone supplementation for erectile dysfunction: results of a meta-analysis. J Urol 2000;164:371-5.

196. Bolona ER, Uraga MV, Haddad RM, Tracz MJ, Sideras K, Kennedy CC, Caples SM, Erwin PJ, Montori VM.Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007 Jan;82(1):20-8.

197. Isidori AM, Giannetta E, Gianfrilli D, Greco EA, Bonifacio V, Aversa A, Isidori A, Fabbri A, Lenzi A.Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf). 2005 Oct;63(4):381-94.

198. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H.Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol. 2004 Aug;172(2):658-63.

199. Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri A.Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf). 2003 May;58(5):632-8.

200. Stepan JJ, Lachman M, Zverina J, Pacovsky V, Baylink DJ. Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab 1989;69:523-7.

201. Goldray D, Weisman Y, Jaccard N, Merdler C, Chen J, Matzkin H. Decreased bone mineral density in elderly men treated with gonadortropin-releaasing hormone agonist decapeptyl (D-Trp6-GnRH). J Clin Endocrinol Metab 1993;76:288-290.

202. Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997;157:439-444.

203. Eriksson S, Eriksson A, Stege R, Carlstrom K. Bone mineral density in patients with prostate cancer treated with orchiectomy and with estrogens. Calcif Tissue Int 1995;57:97-99.

204. Goulding A, Gold E. Flutamide-mediated androgen blockade evokes osteopenia in the female rat. J Bone Mineral Res 1993;8:763-769.

205. Finkelstein JS, Klibanski A, Neer RM, Grrenspan SL, Rosenthal DI, Crowley Jr WF. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med 1987;106:354-361.

206. Bonjour J-P, Theintz G, Buchs B, Slosman D, Rizzoli R. Critical years and stages of puberty for spinal and femoral bone mass and accumulation during adolescence. J Clin Endocrinol Metab 1991;73:555-563.

207. Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997;82:2386-90.

208. Leifke E, Korner HC, Link TM, Behre HM, Peters PE, Nieschlag E. Effects of testosterone replacement therapy on cortical and trabecular bone mineral density, vertebral body area and paraspinal muscle area in hypogonadal men. Eur J Endocrinol 1998;138:51-58.

209. Guo CY, Jones TH, Eastell R.Treatment of isolated hypogonadotropic hypogonadism effect on bone mineral density and bone turnover. J Clin Endocrinol Metab. 1997 Feb;82(2):658-65.

210. Aminorroaya A, Kelleher S, Conway AJ, Ly LP, Handelsman DJ.Adequacy of androgen replacement influences bone density response to testosterone in androgen-deficient men. Eur J Endocrinol. 2005 Jun;152(6):881-6.

211. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman N.Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin Endocrinol (Oxf). 2001 Jun;54(6):739-50.

212. Stanley HL, Schmitt BP, Poses RM, Deiss WP. Does hypogonadism contribute to the occurrence of a minimal trauma hip fracture in elderly men? J Am Geriatr Soc 1991;39:766-71.

213. Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG.Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci. 2001 May;56(5):M266-72.

214. Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL.Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab. 2004 Feb;89(2):503-10.

215. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999; 84:1966-1972.

216. Anderson FH, Francis RM, Peaston RT, Eastell HJ. Androgen supplementation in eugonadal men with osteoporosis: effects of 6 months treatment on markers of bone formation and resorption. J Bone Mineral Res 1997;12:472-478.

217. Leder BZ, LeBlanc KM, Schoenfeld DA, Eastell R, Finkelstein JS.Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab. 2003 Jan;88(1):204-10.

218. Falahati-Nini A, Riggs BL, Atkinson EJ, O'Fallon WM, Eastell R, Khosla S.Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest. 2000 Dec;106(12):1553-60.

219. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman N.Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin Endocrinol (Oxf). 2001 Jun;54(6):739-50.

220. Sims NA, Clement-Lacroix P, Minet D, Fraslon-Vanhulle C, Gaillard-Kelly M, Resche-Rigon M, Baron R. A functional androgen receptor is not sufficient to allow estradiol to protect bone after gonadectomy in estradiol receptor-deficient mice. J Clin Invest. 2003 May;111(9):1319-27.

221. Syed FA, Modder UI, Fraser DG, Spelsberg TC, Rosen CJ, Krust A, Chambon P, Jameson JL, Khosla S.Skeletal effects of estrogen are mediated by opposing actions of classical and nonclassical estrogen receptor pathways. J Bone Miner Res. 2005 Nov;20(11):1992-2001.

222. Vidal O, Lindberg MK, Hollberg K, Baylink DJ, Andersson G, Lubahn DB, Mohan S, Gustafsson JA, Ohlsson C.Estrogen receptor specificity in the regulation of skeletal growth and maturation in male mice. Proc Natl Acad Sci U S A. 2000 May 9;97(10):5474-9.

223. Lindberg MK, Alatalo SL, Halleen JM, Mohan S, Gustafsson JA, Ohlsson C.Estrogen receptor specificity in the regulation of the skeleton in female mice. J Endocrinol. 2001 Nov;171(2):229-36.

224. Vandenput L, Ederveen AG, Erben RG, Stahr K, Swinnen JV, Van Herck E, Verstuyf A, Boonen S, Bouillon R, Vanderschueren D.Testosterone prevents orchidectomy-induced bone loss in estrogen receptor-alpha knockout mice. Biochem Biophys Res Commun. 2001 Jul 6;285(1):70-6.

225. Vandenput L, Swinnen JV, Boonen S, Van Herck E, Erben RG, Bouillon R, Vanderschueren D.Role of the androgen receptor in skeletal homeostasis: the androgen-resistant testicular feminized male mouse model. J Bone Miner Res. 2004 Sep;19(9):1462-70.

226. Venken K, De Gendt K, Boonen S, Ophoff J, Bouillon R, Swinnen JV, Verhoeven G, Vanderschueren D.Relative impact of androgen and estrogen receptor activation in the effects of androgens on trabecular and cortical bone in growing male mice: a study in the androgen receptor knockout mouse model. J Bone Miner Res. 2006 Apr;21(4):576-85.

227. Colvard DS, Eriksen EF, Keeting PE, Wilson EM, Lubahn DB, French FS, Riggs BL, Spelsberg TC. Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Acad Sci U S A. 1989;86:854-7.

228. Riggs BL, Khosla S, Melton LJ 3rd.Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev. 2002 Jun;23(3):279-302.

229. Kasperk CH, Wergedal JE, Farley JR, Linkhart TA, Turner RT, Baylink DJ 1989 Androgens directly stimulate proliferation of bone cells in vitro. Endocrinology 124:1576–1578

230. Zhang XZ, Kalu DN, Erbas B, Hopper JL, Seeman E.The effects of gonadectomy on bone size, mass, and volumetric density in growing rats are gender-, site-, and growth hormone-specific.J Bone Miner Res. 1999 May;14(5):802-9.

231. Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Bodenner DL, Han L, Han K, DiGregorio GB, Katzenellenbogen JA, Katzenellenbogen BS, Roberson PK, Weinstein RS, Jilka RL, Manolagas SC. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell. 2001; 104:719-730.

232. Kousteni, S. et al.2002. Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science. 298:843-846.

233. Maccoby EE JC. The Psychology of Sex Differences. Stanford, CA: Stanford University Press, 1974.

234. Christiansen K.Sex hormone-related variations of cognitive performance in !Kung San hunter-gatherers of Namibia. Neuropsychobiology. 1993;27(2):97-107.

235. Barrett-Connor E, Goodman-Gruen D, Patay B.Endogenous sex hormones and cognitive function in older men. J Clin Endocrinol Metab. 1999 Oct;84(10):3681-5.

236. Moffat SD, Zonderman AB, Metter EJ, Blackman MR, Harman SM, Resnick SM.Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metab. 2002 Nov;87(11):5001-7.

237. Gouchie C, Kimura D.The relationship between testosterone levels and cognitive ability patterns. Psychoneuroendocrinology. 1991;16(4):323-34.

238. Silverman I, Kastuk D, Choi J, Phillips K.Testosterone levels and spatial ability in men. Psychoneuroendocrinology. 1999 Nov;24(8):813-22.

239. Hooven CK, Chabris CF, Ellison PT, Kosslyn SM.The relationship of male testosterone to components of mental rotation. Neuropsychologia. 2004;42(6):782-90.

240. Moffat SD, Hampson E.A curvilinear relationship between testosterone and spatial cognition in humans: possible influence of hand preference. Psychoneuroendocrinology. 1996 Apr;21(3):323-37.

241. Nass R, Baker S.Androgen effects on cognition: congenital adrenal hyperplasia. Psychoneuroendocrinology. 1991;16(1-3):189-201.

242. Jones BA, Watson NV.Spatial memory performance in androgen insensitive male rats. Physiol Behav. 2005 Jun 2;85(2):135-41.

243. Janowsky JS, Oviatt SK, Orwoll ES. Testosterone influences spatial cognition in older men. Behav Neurosci 1994;108:325-32.

244. Cherrier MM, Anawalt BD, Herbst KL, Amory JK, Craft S, Matsumoto AM, Bremner WJ.Cognitive effects of short-term manipulation of serum sex steroids in healthy young men. J Clin Endocrinol Metab. 2002 87:3090-3096.

245. Vaughan C, Goldstein FC, Tenover JL.Exogenous testosterone alone or with finasteride does not improve measurements of cognition in healthy older men with low serum testosterone.J Androl. 2007 Nov-Dec;28(6):875-82.

246. Cherrier MM, Matsumoto AM, Amory JK, Johnson M, Craft S, Peskind ER, Raskind MA.Characterization of verbal and spatial memory changes from moderate to supraphysiological increases in serum testosterone in healthy older men. Psychoneuroendocrinology. 2007 Jan;32(1):72-9.

247. Cherrier MM, Matsumoto AM, Amory JK, Asthana S, Bremner W, Peskind ER, Raskind MA, Craft S.Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment. Neurology. 2005 Jun 28;64(12):2063-8.

248. O'Connor DB, Archer J, Hair WM, Wu FC.Activational effects of testosterone on cognitive function in men. Neuropsychologia. 2001;39(13):1385-94.

249. Alexander GM, Swerdloff RS, Wang C, Davidson T, McDonald V, Steiner B, Hines M.Androgen-behavior correlations in hypogonadal men and eugonadal men. II. Cognitive abilities. Horm Behav. 1998 Apr;33(2):85-94.

250. Van Goozen SH, Cohen-Kettenis PT, Gooren LJ, Frijda NH, Van de Poll NE. Gender differences in behaviour: activating effects of cross-sex hormones. Psychoneuroendocrinology 1995; 20:343-63.

251. Van Goozen SH, Cohen-Kettenis PT, Gooren LJ, Frijda NH, Van de Poll NE. Activating effects of androgens on cognitive performance: causal evidence in a group of female-to-male transsexuals. Neuropsychologia 1994; 32:1153-7.

252. Sherwin BB. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology 1988;13(3):345-357.

253. Simerly RB, Chang C, Muramatsu M, Swanson LW. Distribution of androgen and estrogen receptor mRNA-containing cells in the rat brain: an in situ hybridization study. J Comp Neurol 1990; 294:76-95

254. Dorner G, Hinz G. Androgen dependent brain differentiation and life span. Endokrinologie 1975; 65:378-80.

255. Lu S, Simon NG, Wang Y, Hu S. Neural androgen receptor regulation: effects of androgen and antiandrogen. J Neurobiol 1999; 41:505-11.

256. Lustig RH. Sex hormone modulation of neural development in vitro. Horm Behav 1994;28:383-95.

257. Rubinow DR, Schmidt PJ. Androgens, brain, and behavior. Am J Psychiatry 1996; 153:974-84.

258. Tobin VA, Millar RP, Canny BJ. Testosterone acts directly at the pituitary to regulate gonadotropin- releasing hormone-induced calcium signals in male rat gonadotropes. Endocrinology 1997; 138:3314-9.

259. Wang C, Alexander G, Berman N, Salehian B, Davidson T, McDonald V, Steiner B, Hull L, Callegari C, Swerdloff RS. Testosterone replacement therapy improves mood in hypogonadal men--a clinical research center study. J Clin Endocrinol Metab 1996;81(10):3578-83.

260. Gray PB, Singh AB, Woodhouse LJ, Storer TW, Casaburi R, Dzekov J, Dzekov C, Sinha-Hikim I, Bhasin S.Dose-dependent effects of testosterone on sexual function, mood, and visuospatial cognition in older men. J Clin Endocrinol Metab. 2005 Jul;90(7):3838-46.

261. Arlt W, Callies F, van Vlijmen JC, Koehler I, Reincke M, Bidlingmaier M, Huebler D, Oettel M, Ernst M, Schulte HM, Allolio B. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med 1999;341(14):1013-20.

262. Pope HG Jr, Cohane GH, Kanayama G, Siegel AJ, Hudson JI.Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am J Psychiatry. 2003 Jan;160(1):105-11.

263. Seidman SN, Miyazaki M, Roose SP.Intramuscular testosterone supplementation to selective serotonin reuptake inhibitor in treatment-resistant depressed men: randomized placebo-controlled clinical trial. J Clin Psychopharmacol. 2005 Dec;25(6):584-8.

264. Seidman SN, Spatz E, Rizzo C, Roose SP.Testosterone replacement therapy for hypogonadal men with major depressive disorder: a randomized, placebo-controlled clinical trial. J Clin Psychiatry. 2001 Jun;62(6):406-12.

265. Perry PJ, Yates WR, Williams RD, Andersen AE, MacIndoe JH, Lund BC, Holman TL.Testosterone therapy in late-life major depression in males. J Clin Psychiatry. 2002 Dec;63(12):1096-101.

266. Grinspoon S, Corcoran C, Stanley T, Baaj A, Basgoz N, Klibanski A. Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men. J Clin Endocrinol Metab 2000;85:60-5.

267. Rabkin JG, Ferrando SJ, Wagner GJ, Rabkin R. DHEA treatment for HIV+ patients: effects on mood, androgenic and anabolic parameters. Psychoneuroendocrinology 2000;25(1):53-68.

268. Kouri EM, Lukas SE, Pope HG Jr, Oliva PS. Increased aggressive responding in male volunteers following the administration of gradually increasing doses of testosterone cypionate. Drug Alcohol Depend. 1995;40:73-9.

269. Pope HG Jr, Katz DL. Affective and psychotic symptoms associated with anabolic steroid use. Am J Psychiatry 1988;145:487-90.

270. Wilson IB, Roubenoff R, Knox TA, Spiegleman D, Gorbach SL. Relation of lean body mass to health-related quality of life in persons with HIV. J Acquir Immune Defic Syndrome 2000;24:137-46.

271. Litwin MS, Nied RJ, Dhandani N. Health-related quality of life in men with erectile dysfunction. J Gen Intern Med 1998;13:159-166.

272. Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, Perry HM 3rd. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism. 2000 Sep;49(9):1239-42.

273. T'Sjoen G, Goemaere S, De Meyere M, Kaufman JM. Perception of males' aging symptoms, health and well-being in elderly community-dwelling men is not related to circulating androgen levels. Psychoneuroendocrinology. 2004 Feb;29(2):201-14.

274. Smith KW, Feldman HA, McKinlay JB. Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men. Clin Endocrinol (Oxf). 2000 Dec;53(6):703-11.

275. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, Bhasin S.Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005 Nov;60(11):1451-7.

276. Rolf C, Nieschlag E. Potential adverse effects of long-term testosterone therapy. Baillieres Clin Endocrinol Metab 1998; 12:521-34.

277. Liu PY, Death AK, Handelsman DJ.Androgens and cardiovascular disease. Endocr Rev. 2003 Jun;24(3):313-40.

278. Haffner SM, Laakso M, Miettinen H, Mykkanen L, Karhapaa P, Rainwater DL. Low levels of sex hormone-binding globulin and testosterone are associated with smaller, denser low density lipoprotein in normoglycemic men [see comments]. J Clin Endocrinol Metab 1996; 81:3697-701.

279. Khaw KT, Barrett-Connor E.Endogenous sex hormones, high density lipoprotein cholesterol, and other lipoprotein fractions in men. Arterioscler Thromb. 1991 May-Jun;11(3):489-94.

280. De Pergola G, De Mitrio V, Sciaraffia M, et al. Lower androgenicity is associated with higher plasma levels of prothrombotic factors irrespective of age, obesity, body fat distribution, and related metabolic parameters in men. Metabolism 1997; 46:1287-93.

281. Crist DM, Peake GT, Stackpole PJ. Lipemic and lipoproteinemic effects of natural and synthetic androgens in humans. Clin Exp Pharmacol Physiol 1986; 13:513-8.

282. Herbst KL, Amory JK, Brunzell JD, Chansky HA, Bremner WJ. Testosterone administration to men increases hepatic lipase activity and decreases HDL and LDL size in 3 wk. Am J Physiol Endocrinol Metab. 2003 284:E1112-E1118.

283. Hurley BF, Seals DR, Hagberg JM, et al. High-density-lipoprotein cholesterol in bodybuilders v powerlifters. Negative effects of androgen use. JAMA 1984; 252:507-13.

284. Thompson PD, Cullinane EM, Sady SP, et al. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 1989; 261:1165-8.

285. Langer C, Gansz B, Goepfert C, Engel T, Uehara Y, von Dehn G, Jansen H, Assmann G, von Eckardstein A: Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages. Biochem Biophys Res Commun 2002 296:1051–1057.

286. Mauras N, Hayes V, Welch S, et al. Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab 1998; 83:1886-92.

287. Khaw KT, Barrett-Connor E. Lower endogenous androgens predict central adiposity in men. Ann Epidemiol 1992; 2:675-82.

288. Seidell JC, Bjorntorp P, Sjostrom L, Kvist H, Sannerstedt R. Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism 1990;

289. Mårin P, Odén B, Björntorp P. Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: Effects of androgens. J Clin Endocrinol Metab 1995; 80:239-243.

290. Marin P, Holmang S, Jonsson L, et al. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. International J Obesity 1992;16:991-997.

291. Rebuffe-Scrive M, Marin P, Bjorntorp P. Effect of testosterone on abdominal adipose tissue in men. Int J Obes 1991;15:791-5.

292. Holmang A, Bjorntorp P. The effects of testosterone on insulin sensitivity in male rats. Acta Physiol Scand 1992; 146:505-10.

293. Hobbs CJ, Jones RE, Plymate SR. Nandrolone, a 19-nortestosterone, enhances insulin-independent glucose uptake in normal men [see comments]. J Clin Endocrinol Metab 1996; 81:1582-5.

294. Ramirez ME, McMurry MP, Wiebke GA. Evidence for sex steroid inhibition of lipoprotein lipase in men: comparison of abdominal and femoral adipose tissue. Metabolism 1997;46:179-85.

295. Defay R, Papoz L, Barny S, Bonnot-Lours S, Caces E, Simon D. Hormonal status and NIDDM in the European and Melanesian populations of New Caledonia: a case-control study. The Caledonia Diabetes Mellitus (CALDIA) Study Group. Int J Obes Relat Metab Disord 1998; 22:927-34.

296. Haffner SM, Shaten J, Stern MP, Smith GD, Kuller L. Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996;143:889-97.

297. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care 2000;23(4):490-4.

298. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL; Rancho Bernardo Study.Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care. 2002 Jan;25(1):55-60.

299. Endre T, Mattiasson I, Berglund G, Hulthen UL. Low testosterone and insulin resistance in hypertension-prone men. J Hum Hypertens 1996; 10:755-61.

300. Glueck CJ, Glueck HI, Stroop D, Speirs J, Hamer T, Tracy T: Endogenous testosterone, fibrinolysis, and coronary heart disease risk in hyperlipidemic men. J Lab Clin Med 1993 122:412–420.

301. Ng MK, Liu PY, Williams AJ, Nakhla S, Ly LP, Handelsman DJ, Celermajer DS: Prospective study of effect of androgens on serum inflammatory markers in men. Arterioscler Thromb Vasc Biol 2002 22:1136–1141.

302. Singh AB, Hsia S, Alaupovic P, Sinha-Hikim I, Woodhouse L, Buchanan TA, Shen R, Bross R, Berman N, Bhasin S.The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab. 2002 Jan;87(1):136-43.

303. Phillips GB, Pinkernell BH, Jing TY. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb 1994;14:701-6.

304. Tibblin G, Adlerberth A, Lindstedt G, Bjorntorp P. The pituitary-gonadal axis and health in elderly men: a study of men born in 1913. Diabetes 1996; 45:1605-9.

305. Arnlov J, Pencina MJ, Amin S, Nam BH, Benjamin EJ, Murabito JM, Wang TJ, Knapp PE, D'Agostino RB Sr, Bhasin S, Vasan RS.Endogenous sex hormones and cardiovascular disease incidence in men. Ann Intern Med. 2006 Aug 1;145(3):176-84.

306. Wu SZ, Weng XZ. Therapeutic effects of an androgenic preparation on myocardial ischemia and cardiac function in 62 elderly male coronary heart disease patients. Chin Med J (Engl) 1993; 106:415-8.

307. Jaffe MD. Effect of testosterone cypionate on postexercise ST segment depression. Br Heart J. 1977;39:1217-22.

308. Ong PJ, Patrizi G, Chong WC, Webb CM, Hayward CS, Collins P. Testosterone enhances flow-mediated brachial artery reactivity in men with coronary artery disease. Am J Cardiol 2000 Jan 15;85(2):269-72.

309. Rosano GM, Leonardo F, Pagnotta P, Pelliccia F, Panina G, Cerquetani E, della Monica PL, Bonfigli B, Volpe M, Chierchia SL. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 1999:1666-70.

310. Webb CM, Adamson DL, de Zeigler D, Collins P. Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am J Cardiol 1999;83(3):437-9.

311. English KM, Steeds RP, Jones TH, Diver MJ, Channer KS: Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation 102:1906–1911, 2000.

312. Thompson PD, Ahlberg AW, Moyna NM, Duncan B, Ferraro-Borgida M, White CM, McGill CC, Heller GV: Effect of intravenous testosterone on myocardial ischemia in men with coronary artery disease. Am Heart J 143:249–256, 2002

313. Yue P, Chatterjee K, Beale C, Poole-Wilson PA, Collins P: Testosterone relaxes rabbit coronary arteries and aorta. Circulation 1995 91:1154–1160.

314. Nathan L, Shi W, Dinh H, Mukherjee TK, Wang X, Lusis AJ, Chaudhuri G. Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase. Proc Natl Acad Sci U S A. 2001 98:3589-3593.

315. Alexandersen P, Haarbo J, Byrjalsen I, Lawaetz H, Christiansen C: Natural androgens inhibit male atherosclerosis: a study in castrated, cholesterol-fed rabbits. Circ Res 1999 84:813–819.

316. Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham GR.Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl. 2003 May-Jun;24(3):299-311.

317. Fowler, J. E., Jr. and W. F. Whitmore, Jr. (1981). The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 126(3): 372-5.

318. Manni, A., M. Bartholomew, R. Caplan, A. Boucher, R. Santen, A. Lipton, H. Harvey, M. Simmonds, D. White-Hershey, R. Gordon. (1988). Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. J Clin Oncol 6(9): 1456-66.

319. Babaian R. J., D. A. Johnston, W. Naccarato, A. Ayala, V. A. Bhadkamkar, H. H. Fritsche. (2001). The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml: relation to biopsy strategy. J Urol 165(3): 757-60.

320. Gatling, R. R. (1990). Prostate carcinoma: an autopsy evaluation of the influence of age, tumor grade, and therapy on tumor biology. South Med J 83(7): 782-4.

321. Greenlee, R. T., T. Murray, S. Bolden, P. A. Wingo. (2000). Cancer statistics, 2000. CA Cancer J Clin 50(1): 7-33.

322. Guileyardo, J. M., W. D. Johnson, R. A. Welsh, K. Akazaki, P. Correa. (1980). Prevalence of latent prostate carcinoma in two U.S. populations. J Natl Cancer Inst 65(2): 311-6.

323. Hsing, A. W., L. Tsao and S. S. Devesa (2000). International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 85(1): 60-7.

324. Hsing, A. W. and S. S. Devesa (2001). Trends and patterns of prostate cancer: what do they suggest? Epidemiol Rev 23(1): 3-13.

325. Landis, S. H., T. Murray, S. Bolden, P. A. Wingo. (1998). Cancer statistics, 1998. CA Cancer J Clin 48(1): 6-29.

326. Landis, S. H., T. Murray, S. Bolden, P. A. Wingo. (1999). Cancer statistics, 1999. CA Cancer J Clin 49(1): 8-31, 1.

327. Holmang, S., P. Marin, G. Lindstedt, H. Hedelin. (1993). Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men. Prostate 23(2): 99-106.

328. Morgentaler A, Bruning CO 3rd, DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA1996 Dec 18;276(23):1904-6

329. Hoffman, M. A., W. C. DeWolf and A. Morgentaler (2000). Is low serum free testosterone a marker for high grade prostate cancer? J Urol 163(3): 824-7.

330. Schatzl, G., S. Madersbacher, T. Thurridl, J. Waldmuller, G. Kramer, A. Haitel, M. Marberger. (2001). High-grade prostate cancer is associated with low serum testosterone levels. Prostate 47(1): 52-8.

331. Ahluwalia, B., M. A. Jackson, G. W. Jones, A. O. Williams, M. S. Rao, S. Rajguru. (1981). Blood hormone profiles in prostate cancer patients in high-risk and low- risk populations. Cancer 48(10): 2267-73.

332. Andersson, S. O., H. O. Adami, R. Bergstrom, L. Wide. (1993). Serum pituitary and sex steroid hormone levels in the etiology of prostatic cancer--a population-based case-control study. Br J Cancer 68(1): 97-102.

333. Demark-Wahnefried, W., S. M. Lesko, M. R. Conaway, C. N. Robertson, R. V. Clark, B. Lobaugh, B. J. Mathias, T. S. Strigo, D. F. Paulson. (1997). Serum androgens: associations with prostate cancer risk and hair patterning. J Androl 18(5): 495-500.

334. Dorgan, J. F., D. Albanes, J. Virtamo, O. P., Heinonen, D. W. Chandler, M. Galmarini, L. M. McShane, M. J. Barrett, J. Tangrea, P. R. Taylor. (1998). Relationships of serum androgens and estrogens to prostate cancer risk: results from a prospective study in Finland. Cancer Epidemiol Biomarkers Prev 7(12): 1069-74.

335. Eaton, N. E., G. K. Reeves, P. N. Appleby, T. J. Key. (1999). Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br J Cancer 80(7): 930-4.

336. Gann, P. H., C. H. Hennekens, J. Ma, C. Longcope, M. J. Stampfer. (1996). Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 88(16): 1118-26.

337. Hawk, E., R. A. Breslow and B. I. Graubard (2000). Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the first National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev 9(5): 523-7.

338. Heikkila, R., K. Aho, M. Heliovaara, M. Hakama, J. Marniemi, A. Reunanen, P. Knekt. (1999). Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study. Cancer 86(2): 312-5.

339. Hsing, A. W. and G. W. Comstock (112). Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomarkers Prev 2(1): 27-32.

340. Hulka, B. S., J. E. Hammond, G. DiFerdinando, D. D. Mickey, F. A. Fried, H. Checkoway, W. E. Stumpf, W. C. Beckman, Jr., T. D. Clark. (76). Serum hormone levels among patients with prostatic carcinoma or benign prostatic hyperplasia and clinic controls. Prostate 11(2): 171-82.

341. Nomura, A., L. K. Heilbrun, G. N. Stemmermann, H. L. Judd. (1988). Prediagnostic serum hormones and the risk of prostate cancer. Cancer Res 48(12): 3515-7.

342. Nomura, A. M., G. N. Stemmermann, P. H. Chyou, B. E. Henderson, F. Z. Stanczyk. (1996). Serum androgens and prostate cancer. Cancer Epidemiol Biomarkers Prev 5(8): 621-5.

343. Shaneyfelt, T., R. Husein, G. Bubley, C. S. Mantzoros. (2000). Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 18(4): 847-53.

344. Slater S, Oliver RT. Testosterone: its role in development of prostate cancer and potential risk from use as hormone replacement therapy. Drugs Aging 2000: 17:431-9.

345. Vatten, L. J., G. Ursin, R. K. Ross, F. Z. Stanczyk, R. A. Lobo, S. Harvei, E. Jellum. (1997). Androgens in serum and the risk of prostate cancer: a nested case- control study from the Janus serum bank in Norway. Cancer Epidemiol Biomarkers Prev 6: 967-969.

346. Wolk, A, Andersson OS, Bergstrom R. 1997 Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 89: 820.

347. Barrett-Connor E, Garland C, McPhillips JB, Khaw KT, Wingard DL. 1990 A prospective, population-based study of androstenedione, estrogens, and prostatic cancer. Cancer Res 50: 169-173.

348. Mohr, B. A., H. A. Feldman, L. A. Kalish, C. Longcope, J. B. McKinlay. (2001). Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts Male Aging Study. Urology 57: 930-935.

349. Platz EA, Leitzmann MF, Rifai N, Kantoff PW, Chen YC, Stampfer MJ, Willett WC, Giovannucci E.Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1262-9.

350. Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, Veltri RW, Makarov DV, Partin AW, Bostwick DG, Macairan ML, Nelson PS. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 2006;296:2351-61.

351. Page ST, Lin DW, Mostaghel EA, Hess DL, True LD, Amory JK, Nelson PS, Matsumoto AM, Bremner WJ. Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab 2006;91:3850-6.

352. Behre HM, B. J., Nieschlag E. (1994). Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol (Oxf) 40: 341-349.

353. Cooper CS, Perry PJ, Sparks AE, MacIndoe JH, Yates WR, Williams RD. Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men. J Urol 1998;159:441-443.

354. Douglas, T. H., R. R. Connelly, D. G. McLeod, S. J. Ericsson, R. Barren, 3rd, G. P. Murphy. (1995). Effect of exogenous testosterone replacement on prostate-specific antigen and prostate-specific membrane antigen levels in hypogonadal men. J Surg Oncol 59(4): 246-50.

355. Guay, A. T., J. B. Perez, W. A. Fitaihi, M. Vereb. (2000). Testosterone treatment in hypogonadal men: prostate-specific antigen level and risk of prostate cancer. Endocr Pract 6(2): 132-8.

356. Meikle AW, Arver S, Dobs AS, Adolfsson J, Sanders SW, Middleton RG et al. Prostate size in hypogonadal men treated with a nonscrotal permeation- enhanced testosterone transdermal system. Urology 1997; 49:191-196.

357. Sasagawa I, Nakada T, Kazama T, Satomi S, Terada T, Katayama T. Volume change of the prostate and seminal vesicles in male hypogonadism after androgen replacement therapy. Int Urol Nephrol 1990; 22(3):279-284.

358. Shibasaki, T., I. Sasagawa, Y. Suzuki, H. Yazawa, O. Ichiyanagi, S. Matsuki, M. Miura, T. Nakada. (2001). Effect of testosterone replacement therapy on serum PSA in patients with Klinefelter syndrome. Arch Androl 47(3): 173-6.

359. Svetec DA, Canby ED, Thompson IM, Sabanegh ES, Jr. The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfunction. J Urol 1997;158:1775-1777.

360. Gormley, G. J., E. Stoner, R. C. Bruskewitz, J. Imperato-McGinley, P. C. Walsh, J. D. McConnell, G. L. Andriole, J. Geller, B. R. Bracken, J. S. Tenover. (1992). “The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group [see comments].” N Engl J Med 327(17): 1185-91.

361. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr.The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215-24.

362. Manseck, A., C. Pilarsky, S. Froschermaier, M. Menschikowski, M. P. Wirth. (1998). Diagnostic significance of prostate-specific antigen velocity at intermediate PSA serum levels in relation to the standard deviation of different test systems. Urol Int 60(1): 25-27.

363. Riehmann, M., P. R. Rhodes, T. D. Cook, G. S. Grose, R. C. Bruskewitz. (1993). Analysis of variation in prostate-specific antigen values. Urology 42(4): 390-7.

364. Wenzl, T. B., M. Riehmann, T. D. Cook, R. C. Bruskewitz. (1998). Variation in PSA values in patients without malignancy. Urology 52(5): 932.

365. Carter, H. B. and J. D. Pearson (1993). PSA velocity for the diagnosis of early prostate cancer. A new concept. Urol Clin North Am 20(4): 665-670.

366. Carter HB, Pearson JD, Waclawiw Z, Metter EJ, Chan DW, Guess HA, Walsh PC. Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. Urology 1995(b);45:591-6.

367. Fang, J., E. J. Metter, P. Landis, H. B. Carter. (2002). PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml. Urology 59(6): 889-93; discussion 893-894.

368. Fang, J., E. J. Metter, P. Landis, D. W. Chan, C. H. Morrell, H. B. Carter. (2001). Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology 58(3): 411-6.

369. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Mac RP, Lee M, Yarasheski KE, Sinha-Hikim I, Dzekov C, Dzekov J, Magliano L, Storer TW.Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab. 2005 Feb;90(2):678-88.

370. Wu FC, Farley TM, Peregoudov A, Waites GM. Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Fertil Steril 1996 Mar;65(3):626-36.

371. Carter HB, Pearson JD, Metter EJ, Chan DW, Andres R, Fozard JL et al. Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate 1995(a);27:25-31.

372. Fried W, Marver D, Lange RD, Gurney CW. Studies on the erythropoietic stimulating factor in the plasma of mice after receiving testosterone. J Lab Clin Med 1966; 68:947-951.

373. Rencricca NJ, Solomon J, Fimian WJ, Jr., Howard D, Rizzoli V, Stohlman F, Jr. The effect of testosterone on erythropoiesis. Scand J Haematol 1969; 6(6):431-436.

374. Naets JP, Wittek M. The mechanism of action of androgens on erythropoiesis. Ann N Y Acad Sci 1968; 149(1):366-376.

375. Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999; 84:3469-3478.

376. Cistulli PA, Grunstein RR, Sullivan CE. Effect of testosterone administration on upper airway collapsibility during sleep. Am J Respir Crit Care Med 1994; 149:530-532.

377. Dexter DD, Dovre EJ. Obstructive sleep apnea due to endogenous testosterone production in a woman. Mayo Clin Proc 1998;73:246-248.

378. Emery MJ, Hlastala MP, Matsumoto AM. Depression of hypercapnic ventilatory drive by testosterone in the sleeping infant primate. J Appl Physiol 1994; 76(4):1786-1793.

379. Grunstein RR. Metabolic aspects of sleep apnea. Sleep 1996;19(10 Suppl):S218-S220.

380. Matsumoto AM, Sandblom RE, Schoene RB, Lee KA, Giblin EC, Pierson DJ et al. Testosterone replacement in hypogonadal men: effects on obstructive sleep apnoea, respiratory drives, and sleep. Clin Endocrinol (Oxf) 1985; 22(6):713-721.

381. Schneider BK, Pickett CK, Zwillich CW, Weil JV, McDermott MT, Santen RJ et al. Influence of testosterone on breathing during sleep. J Appl Physiol 1986; 61(2):618-623.

382. Seymour FI, Duffy C, Korner A. 2002 A case of authentic fertility in a man of 94. JAMA 105:1423-1424.

383. Plas E, Berger P, Hermann M, Pfluger H. 2000 Effects of aging on male fertility? Exp Gerontol 35:543-551.

384. Rolf C, Nieschlag E. 2001 Reproductive functions, fertility and genetic risks of ageing men. Exp Clin Endocrinol Diabetes 109:68-74.

385. American Fertility Society 1990: New guidelines for the use of semen donor insemination. Fertil Steril 53 (Suppl 1): 1S-13S.

386. American Society for Reproductive Medicine1998: Guidelines for gamete and embryo donation. http://www.asrm.org/Media/Practice/gamete.html

387. Silber SJ. 1991 Effects of age on male fertility. Semin Reprod Endocrinol 9:241-248.

388. Kidd SA, Eskenazi B, Wyrobek AJ. 2001 Effects of male age on semen quality and fertility: a review of the literature. Fertil Steril 75:237-248.

389. Sloter E, Nath J, Eskenazi B, Wyrobek AJ.Effects of male age on the frequencies of germinal and heritable chromosomal abnormalities in humans and rodents. Fertil Steril. 2004;81:925-43.

390. Eskenazi B, Wyrobek AJ, Sloter E, Kidd SA, Moore L, Young S, Moore D. 2003 The association of age and semen quality in healthy men. Hum Reprod 18(2): 447-454.

391. Kimura M, Itoh N, Takagi S, Sasao T, Takahashi A, Masumori N, Tsukamoto T. Balance of apoptosis and proliferation of germ cells related to spermatogenesis in aged men. J Androl. 2003 Mar-Apr;24(2):185-91.

392. Härkönen K, Suominen J, Lähdetie J. 2001 Aneuploidy in spermatozoa of infertile men with teratosoospermia. Int J Androl 24:197-205.

393. Luetjens CM, Rolf C, Gassner P, Werny JE, Nieschlag E. 2002 Sperm aneuploidy rates in younger and older men. Hum Reprod 17:1826-1832.

394. Sloter ED, Marchetti F, Eskenazi B, Weldon RH, Nath J, Cabreros D, Wyrobek AJ.Frequency of human sperm carrying structural aberrations of chromosome 1 increases with advancing age. Fertil Steril. 2007;87:1077-86.

395. Wyrobek AJ, Eskenazi B, Young S, Arnheim N, Tiemann-Boege I, Jabs EW, Glaser RL, Pearson FS, Evenson D.Advancing age has differential effects on DNA damage, chromatin integrity, gene mutations, and aneuploidies in sperm. Proc Natl Acad Sci U S A. 2006;103:9601-6.

396. Nieschlag E, Lammers U, Freischem CW, Langer K, Wickings EJ. 1982 Reproductive functions in young fathers and grandfathers. J Clin Endocrinol Metab 55:676-681.

397. Gallardo E, Simon C, Levy M, Guanes PP, Remohi J, Pellicer A. 1996 Effect of age on sperm fertility potential: oocyte donation as a model. Fertil Steril 66:260-264.

398. Levitas E, Lunenfeld E, Weisz N, Friger M, Potashnik G.Relationship between age and semen parameters in men with normal sperm concentration: analysis of 6022 semen samples. Andrologia. 2007 Apr;39(2):45-50.

399. de La Rochebrochard E, de Mouzon J, Thépot F, Thonneau P; French National IVF Registry (FIVNAT) Association. Fathers over 40 and increased failure to conceive: the lessons of in vitro fertilization in France. Fertil Steril 2006;85:1420-4.

400. Hellstrom WJ, Overstreet JW, Sikka SC, Denne J, Ahuja S, Hoover AM, Sides GD, Cordell WH, Harrison LM, Whitaker JS.Semen and sperm reference ranges for men 45 years of age and older. J Androl. 2006 May-Jun;27(3):421-8.

401. Handelsman DJ. Male reproductive aging: human fertility, androgens and hormone dependent disease. Novartis Foundation Symposium 2002;242:66-77.

402. Johnson L, Zane RS, Petty CS, Neaves WB. 1984 Quantification of the human Sertoli cell population: its distribution, relation to germ cell numbers, and age-related decline. Biol Reprod. Nov; 31(4):785-95.

403. Kimura M, Itoh N, Takagi S, Sasao T, Takahashi A, Masumori N, Tsukamoto T. Balance of apoptosis and proliferation of germ cells related to spermatogenesis in aged men. J Androl. 2003 Mar-Apr;24(2):185-91.

404. Tulina N, Matunis E 2001 Control of stem cell self-renewal in Drosophila spermatogenesis by JAK-STAT signaling. Science 294:2546-9.

405. Black A, Lane MA. 2002 Nonhuman primate models of skeletal and reproductive aging. Gerontology 48:72-80.

406. Greunewald DA, Naai MA, Hes DL, Matsumoto AM. 1994 The Brown Norway rat as a model of male reproductive aging: evidence for both primary and secondary testicular failure. J Gerontol 49:B42-B50.

407. Wang C, Leung A, Sinha-Hikim AP. 1993 Reproductive aging in the male brown-Norway rat: a model for the human. Endocrinology 133:2773-2781.

408. Taylor GT, Weiss J, Pitha J. 1988 Epididymal sperm profiles in young adult, middle-aged, and testosterone-supplemented old rats. Gamete Res 19:401-409.

409. Oakes CC, Smiraglia DJ, Plass C, Trasler JM, Robaire B. 2003 Aging results in hypermethylation of ribosomal DNA in sperm and liver of male rats. Proc Natl Acad Sci U S A 100:1775-1780.

410. Edelmann P, Gallant J. 1977 On the translational error theory of aging. Proc Natl Acad Sci U S A 74:3396-3398

411. Marden JH, Rogina B, Montooth KL, Helfand SL. 2003 Conditional tradeoffs between aging and organismal performance of Indy long-lived mutant flies. PNAS 100:3369-3373.

412. Jones LS, Berndtson WE. 1986 A quantitative study of Sertoli cell and germ cell populations as related to sexual development and aging in the stallion. Biol Reprod Aug;35(1):138-48

413. Tenover JS, McLachlan RI, Dahl KD, Burger HG, de Kretser DM, Bremner WJ. Decreased serum inhibin levels in normal elderly men: evidence for a decline in Sertoli cell function with aging. J Clin Endocrinol Metab. 1988 Sep;67(3):455-9.

414. Bohring C, Krause W.Serum levels of inhibin B in men of different age groups. Aging Male. 2003 Jun;6(2):73-8.

415. Mahmoud AM, Goemaere S, De Bacquer D, Comhaire FH, Kaufman JM.Serum inhibin B levels in community-dwelling elderly men. Clin Endocrinol (Oxf). 2000 Aug;53(2):141-7.

416. Haji M, Tanaka S, Nishi Y, Yanase T, Takayanagi R, Hasegawa Y, Sasamoto S, Nawata H.Sertoli cell function declines earlier than Leydig cell function in aging Japanese men. Maturitas. 1994 Feb;18(2):143-53.

417. Kaler LW, Neaves WB. Attrition of the human Leydig cell population with advancing age. Anat Rec 1978;192(4):513-8.;

418. Neaves WB, Johnson L, Petty CS. Age-related change in numbers of other interstitial cells in testes of adult men: evidence bearing on the fate of Leydig cells lost with increasing age. Biol Reprod. 1985 Aug;33(1):259-69;

419. Paniagua R, Amat P, Nistal M, Martin A. Ultrastructure of Leydig cells in human ageing testes. J Anat. 1986 Jun;146:173-83.

420. Neaves WB, Johnson L, Porter JC, Parker CR Jr, Petty CS. Leydig cell numbers, daily sperm production, and serum gonadotropin levels in aging men. J Clin Endocrinol Metab. 1984 Oct;59(4):756-63.

421. Nistal M, Santamaria L, Paniagua R, Regadera J, Codesal J. Multinucleate Leydig cells in normal human testes. Andrologia. 1986 May-Jun;18(3):268-72.

422. Jung A, Schuppe H-C, Schill W-B. 2002 Compariso of semen quality in older and younger men attending an andrology clinic. Andrologia 34:116-122.

423. Haidl G, Badura B, Hinsch KD, Ghyczy M, Gareiss J, Schill WB. 1993 Disturbances of sperm flagella due to failure of epididymal maturation and their possible relationship to phospholipids. Hum Reprod 8:1070-1073.

424. Handelsman DJ, Staraj S. Testicular size: the effects of aging, malnutrition, and illness. J Androl. 1985 May-Jun;6(3):144-51.

425. Sartorelli EM, Mazzucatto LF, Pina-Neto JM. 2001 Effect of paternal age on human sperm chromosomes. Fertil Steril 76:1119

426. Crow JF. 2000 The origins, patterns and implications of human spontaneous mutation. Nat Rev Genet 1:40-47.

427. Friedman JM. Genetic disease in the offspring of older fathers. Obstet Gynecol. 1981 Jun;57(6):745-9.

428. Regal RR, Cross PK, Lamson SH, Hook EB. 1980 A search for evidence for a paternal age effect independent of a maternal age effect in birth certificate reports of Down’s syndrome in New York State. Am J Epidemiol 112:650.

429. Ferguson-Smith MA, Yates JR. Maternal age specific rates for chromosome aberrations and factors influencing them: report of a collaborative european study on 52,965 amniocenteses. Prenat Diagn 1984;4:5.

430. Fisch H, Hyun G, Golden R, Hensle TW, Olsson CA, Liberson GL. 2003 The influence of paternal age on Down syndrome. J Urology 169:2275-2278.

431. Stene E, Stene J, Stengel-Rutkowski S. A reanalysis of the New York State prenatal diagnosis data on Down's syndrome and paternal age effects. Hum Genet. 1987;77:299-302.

432. Olshan AF, Schnitzer PG, Baird PA. 1994 Paternal age and the risk of congenital heart defects. Teratol 50:80-84.

433. Lian Z-H, Zack MM, Erickson JD. 1986 Paternal age and the occurrence of birth defects. Am J Hum Genet 39:648-660.

434. Brown AS, Schaefer CA, Wyatt RJ, Begg MD, Goetz R, Bresnahan MA, Harkavy-Friedman J, Gorman JM, Malaspina D, Susser ES. 2002 Paternal age and risk of schizophrenia in adult offspring. Am J Psychiatry 159:1528-1533.

435. Lewis CM, Levinson DF, Wise LH, DeLisi LE, Straub RE, Hovatta I, Williams NM, Schwab SG, Pulver AE, Faraone SV, Brzustowicz LM, Kaufmann CA, Garver DL, Gurling HM, Lindholm E, Coon H, Moises HW, Byerley W, Shaw SH, Mesen A, Sherrington R, O'Neill FA, Walsh D, Kendler KS, Ekelund J, Paunio T, Lonnqvist J, Peltonen L, O'Donovan MC, Owen MJ, Wildenauer DB, Maier W, Nestadt G, Blouin JL, Antonarakis SE, Mowry BJ, Silverman JM, Crowe RR, Cloninger CR, Tsuang MT, Malaspina D, Harkavy-Friedman JM, Svrakic DM, Bassett AS, Holcomb J, Kalsi G, McQuillin A, Brynjolfson J, Sigmundsson T, Petursson H, Jazin E, Zoega T, Helgason T. 2003 Genome Scan Meta-Analysis of Schizophrenia and Bipolar Disorder, Part II: Schizophrenia. Am J Hum Genet 73:34-48. Epub 2003 Jun 11.

436. Harlap S, Paltiel O, Deutsch L, Knaanie A, Masalha S, Tiram E, Caplan LS, Malaspina D, Friedlander Y. 2002 Paternal age and preeclampsia. Epidemiol 13:660-667.

437. Zirkin BR, Santulli R, Strandberg JD, Wright WW, Ewing LL. Testicular steroidogenesis in the ageing Brown Norway rat. J Androl 2003;14:118-123.

438. Wright WW, Fiore C, Zirkin BR. The effect of aging on the seminiferous epithelium of the brown Norway rat. J Androl. 1993 Mar-Apr;14(2):110-7.

439. La Magueresse B, Jegou B. In vitro effects of germ cells on the secretory activity of Sertoli cells recovered from rats of different ages. Endocrinology 1988;22:1672-1680.

440. Humphreys PN. Histology of the testes in aging and senile rats. Exp Gerontol 1977;12:27-34.

441. Syntin P, Robaire B. Sperm structural and motility changes during aging in the Brown Norway rat. J Androl 2001 22:235-244

442. Tramer F, Rocco F, Micali F, Sandri G, Panfili E. Antioxidant systems in rat epididymal spermatozoa. Biol Reprod 1998 59:753-758.

443. Serre V, Robaire B. Paternal age affects fertility and progeny outcome in the Brown Norway rat. Fertil Steril. 1998 Oct;70(4):625-31.